 |
市场调查报告书
商品编码
1424384
小儿科抗癫痫药物市场：按药物类型、给药途径、分销管道和地区划分Anti-Epileptic Drugs for Pediatrics Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
价格
简介目录
预计到 2030 年，全球小儿科抗癫痫药物市场规模将从 2023 年的 12.024 亿美元增至 20.347 亿美元，预测期内年复合成长率（CAGR）为 7.8%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2022年 | 2023/2024年市场规模 | 12.024 亿美元 |
| 过去的资料 | 2018-2021 | 预测期 | 2023-2030 |
| 预测期间 2023/2024 至 2030/2031 年复合年增长率： | 7.80% | 2030/2031价值预测 | 20.347 亿美元 |
图 1. 2023 年按地区分類的小儿科抗癫痫药物全球市场占有率(%)
癫痫是一种常见的神经系统疾病，影响全世界各个年龄层的人。然而，这种情况在儿童中更为常见，因为近 70% 的癫痫患者是在成年之前被诊断出来的。抗癫痫药物在控制癫痫发作和改善癫痫儿童患者的生活品质方面发挥着重要作用。这些药物透过控制大脑中异常神经细胞的放电和同步来预防癫痫发作。近年来，广泛的研究和开发导致了新一代小儿科抗癫痫药物的开发和核准，这些药物更有效且副作用更少。这对儿童癫痫患者的药物医嘱遵从性和治疗结果有正面影响。儿童癫痫的原因包括创伤、出生併发症和遗传性疾病。由脑膜炎等脑部感染疾病引起的癫痫称为症状性癫痫，与遗传有关的疾病称为特发性癫痫。
市场动态
全球小儿科抗癫痫药物市场受到儿童癫痫盛行率不断上升的推动。根据世界卫生组织 (WHO) 的数据，全球约 1% 的儿童患有癫痫症。其他因素，例如医疗保健成本上升、癫痫治疗意识增强以及新抗癫痫药物的推出，正在推动市场成长。但也存在市场抑制因素，如市场开拓成本高、儿童用用药核准监管严格等。此外，抗癫痫药物对儿童神经系统的副作用也成为一个问题。同时，疾病修正治疗的研究和开发以及个人化抗癫痫药物治疗方案的发展对于未来的市场进入者来说是显着的机会。
本研究的主要特点
- 本报告对全球小儿科抗癫痫药物市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030年）的市场规模和年复合成长率（CAGR%）。
- 它还强调了各个细分市场的潜在收益成长机会，并为该市场说明了一系列有吸引力的投资提案。
- 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
- 根据公司亮点、产品系列、主要亮点、绩效和策略等参数对全球小儿科抗癫痫药物市场的主要参与者进行了分析。
- 本研究涵盖的主要企业包括赛诺菲、Eisai、辉瑞、UCB SA、Sunovion Pharmaceuticals、雅培、Jazz Pharmaceuticals、Ovid Therapeutics Inc.、SK BIOPHARMACEUTICALS、Alexza Pharmaceuticals, Inc.、Taisho Pharmaceuticals. Holdings、Marinus Pharmaceticals Inc. .、 Xenon Pharmaceuticals Inc.、H. Lundbeck A/S、Teva Pharmaceutical Industries Ltd. 等。
- 该报告的见解将帮助行销人员和经营团队高层就未来的产品发布、升级、市场扩张和行销策略负责人明智的决策。
- 全球小儿科抗癫痫药市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
- 相关人员可以透过用于分析全球小儿科抗癫痫药物市场的各种策略矩阵来促进他们的决策。
目录
第一章 研究目的与前提
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章市场动态、监理与趋势分析
- 市场动态
- 促进因素
- 神经病变的发生率增加
- 增加研发活动
- 抑制因素
- 监管产品召回增加
- 抗癫痫药物的副作用
- 市场机会
- 尚未开发的新兴市场
- 标靶治疗的需求不断增长
- 影响分析
- 监管指引
- 产品发表会
- 主要进展
- PEST分析
- 波特的分析
- 监管场景
- 併购
- 製造商收益
- 按国家/地区分類的医疗保健支出
第四章全球小儿科抗癫痫药物市场－新型冠状病毒感染疾病（COVID-19）影响分析
- 整体影响
- 政府倡议
- COVID-19 对市场的影响
第五章2018-2030年全球小儿科抗癫痫药物市场（依药物类型）
- 第一代抗癫痫药
- 第二代抗癫痫药
- 第三代抗癫痫药
第 6 章 全球小儿科抗癫痫药物市场（依给药途径），2018-2030 年
- 口服
- 可注射的
- 其他（鼻子等）
第7章2018-2030年全球小儿科抗癫痫药物市场（依分销管道）
- 医院药房
- 零售药房
- 网路药房
第八章2018-2030年全球小儿科抗癫痫药物市场（按地区）
- 北美洲
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 其他亚太地区
- 中东
- GCC
- 以色列
- 其他中东地区
- 非洲
- 北非
- 中部非洲
- 南非
第9章 竞争形势
- Sanofi
- Eisai Co., Ltd.
- Pfizer Inc.
- Company Highlight
- UCB SA
- Company Highlight
- Sunovion Pharmaceuticals Inc.
- Abbott
- Jazz Pharmaceuticals plc
- Ovid Therapeutics Inc.
- SK BIOPHARMACEUTICALS
- Alexza Pharmaceuticals, Inc.
- Taisho Pharmaceutical Holdings Co., Ltd.
- Marinus Pharmaceuticals, Inc.
- Xenon Pharmaceuticals Inc.
- Lundbeck A/S
- Teva Pharmaceutical Industries Ltd.
第10章
- 调查方法
- 关于出版商
简介目录
Product Code: CMI823
The global anti-epileptic drugs for pediatrics market size is expected to reach US$ 2,034.7 Mn by 2030, from US$ 1,202.4 Mn in 2023, exhibiting a compound annual growth rate (CAGR) of 7.8% during the forecast period.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023/2024: | US$ 1,202.4 Mn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023/2024 to 2030/2031 CAGR: | 7.80% | 2030/2031 Value Projection: | US$ 2,034.7 Mn |
Figure 1. Global Anti-epileptic Drugs for Pediatrics Market Share (%), By Region, 2023
Epilepsy is a common neurological disorder that affects people of all ages globally. However, it is more prevalent in children as almost 70% of epilepsy cases are diagnosed before reaching adulthood. Anti-epileptic drugs play a crucial role in managing seizures and improving quality of life for pediatric patients suffering from epilepsy. These medications work by controlling abnormal neuronal firing and synchrony in the brain to prevent seizures. In recent years, extensive research has led to the development and approval of newer generation anti-epileptic drugs that are more effective and have less side effects than the earlier drugs for pediatric use. This has positively impacted medication adherence and treatment outcomes for children with epilepsy. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while a genetics related condition is called idiopathic epilepsy.
Market Dynamics
The global anti-epileptic drugs for pediatrics market is driven by the growing prevalence of epilepsy among children. According to the World Health Organization (WHO), epilepsy affects around 1% of children worldwide. Besides this, factors such as increasing healthcare expenditures, rising awareness about epilepsy treatment, and introduction of newer anti-epileptic drugs are fueling the market growth. However, the market faces certain restraints such as high costs associated with drug development and stringent regulations for the approval of pediatric drugs. Moreover, adverse effects of anti-epileptic drugs on developing neurological system of children poses challenges. On the positive side, ongoing research on disease modifying therapies and development of personalized anti-epileptic drug regimens present notable opportunities for market players in the future.
Key features of the study:
- This report provides an in-depth analysis of the global anti-epileptic drugs for pediatrics market, and provides market size (US$ Mn) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global anti-epileptic drugs for pediatrics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- The key companies covered as part of this study include Sanofi, Eisai Co., Ltd., Pfizer Inc., UCB S.A., Sunovion Pharmaceuticals Inc., Abbott, Jazz Pharmaceuticals plc, Ovid Therapeutics Inc., SK BIOPHARMACEUTICALS, Alexza Pharmaceuticals, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Marinus Pharmaceuticals, Inc., Xenon Pharmaceuticals Inc., H. Lundbeck A/S, and Teva Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type upgrade, market expansion, and marketing tactics
- The global anti-epileptic drugs for pediatrics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-epileptic drugs for pediatrics market
Detailed Segmentation:
- Global Anti-Epileptic Drugs for Pediatrics Market, Drug Type:
- First generation anti-epileptic drugs
- Second generation anti-epileptic drugs
- Third generation anti-epileptic drugs
- Global Anti-Epileptic Drugs for Pediatrics Market, Route of Administration:
- Oral
- Injectable
- Others (Nasal, etc.)
- Global Anti-Epileptic Drugs for Pediatrics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Anti-Epileptic Drugs for Pediatrics Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- Company Profiles
- Sanofi
- Eisai Co., Ltd.
- Pfizer Inc.
- UCB S.A.
- Sunovion Pharmaceuticals Inc.
- Abbott
- Jazz Pharmaceuticals plc
- Ovid Therapeutics Inc.
- SK BIOPHARMACEUTICALS
- Alexza Pharmaceuticals, Inc.
- Taisho Pharmaceutical Holdings Co., Ltd.
- Xenon Pharmaceuticals Inc.
- Lundbeck A/S
- Teva Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trend Analysis
- Market Dynamics
- Drivers
- Increasing incidence of neurological disorders
- Increasing research and development activities
- Restraints
- Increasing product recalls by regulatory authorities
- Side effects of anti-epileptic drugs
- Market Opportunities
- Untapped emerging markets
- The rising demand for targeted therapy
- Impact Analysis
- Regulatory Guidelines
- Product Launches
- Key Development
- PEST Analysis
- PORTER's Analysis
- Regulatory Scenario
- Mergers and Acquisitions
- Manufacturer Revenue
- Healthcare Spending by Country
4. Global Anti-Epileptic Drugs for Pediatrics Market - COVID-19 Impact Analysis
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
5. Global Anti-Epileptic Drugs for Pediatrics Market, By Drug Type, 2018-2030, (US$ Mn)
- Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- First generation anti-epileptic drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Second generation anti-epileptic drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Third generation anti-epileptic drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
6. Global Anti-Epileptic Drugs for Pediatrics Market, By Route of Administration, 2018-2030, (US$ Mn)
- Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Injectable
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Others (Nasal, etc.)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
7. Global Anti-Epileptic Drugs for Pediatrics Market, By Distribution Channel, 2018-2030, (US$ Mn)
- Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
8. Global Anti-Epileptic Drugs for Pediatrics Market, By Region, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlight
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- UCB S.A.
- Company Highlight
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sunovion Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Abbott
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Jazz Pharmaceuticals plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ovid Therapeutics Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- SK BIOPHARMACEUTICALS
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alexza Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Taisho Pharmaceutical Holdings Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Marinus Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Xenon Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About Us
